Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1703 in Eosinophilic Asthma
NCT05522439Phase 2Completed
- Sponsor
- Hengrui
- Start
- Dec 2022
- Primary completion
- Sep 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-1703 in eosinophilic asthma (EoA), sponsored by Hengrui. Started Dec 2022; status: completed.
02
Drugs
SHR-1703
03
Conditions
eosinophilic asthma (EoA)
Beyond the preview
Go deeper on NCT05522439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05522439.